Skip to content
10-Q

Quarterly Report

UNITED THERAPEUTICS Corp UTHR

0001082554-25-000023

← back to feed
Filed
Apr 30, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Apr 23, 2025 45.11M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $1.9B
Cash And Equivalents Q1 2025 · Dec 31, 2024 $1.7B
Current Liabilities Q1 2025 · Mar 31, 2025 $721.5M
Current Liabilities Q1 2025 · Dec 31, 2024 $738.1M
Total Liabilities Q1 2025 · Mar 31, 2025 $936.7M
Total Liabilities Q1 2025 · Dec 31, 2024 $920M
Current Assets Q1 2025 · Mar 31, 2025 $3.94B
Current Assets Q1 2025 · Dec 31, 2024 $3.87B
Total Assets Q1 2025 · Mar 31, 2025 $7.74B
Total Assets Q1 2025 · Dec 31, 2024 $7.36B
Shares Diluted Q1 2025 · Mar 31, 2024 49.7M sh
Stock Repurchased Q1 2025 · Mar 31, 2024 $1B
Capex Q1 2025 · Mar 31, 2024 $38.2M
Operating Cash Flow Q1 2025 · Mar 31, 2024 $376.5M
Stockholders Equity Q1 2025 · Mar 31, 2024 $5.34B
Stockholders Equity Q1 2025 · Dec 31, 2023 $5.98B
Eps Diluted Q1 2025 · Mar 31, 2024 $6.17
Eps Basic Q1 2025 · Mar 31, 2024 $6.52
Sga Expense Q1 2025 · Mar 31, 2024 $144.4M
Rd Expense Q1 2025 · Mar 31, 2024 $104.1M
Net Income Q1 2025 · Mar 31, 2024 $306.6M
Operating Income Q1 2025 · Mar 31, 2024 $356.3M
Gross Profit Q1 2025 · Mar 31, 2024 $604.8M
Cost Of Revenue Q1 2025 · Mar 31, 2024 $72.9M
Revenue Q1 2025 · Mar 31, 2024 $677.7M